期刊文献+

测定血清CA_(125)水平在卵巢癌的临床意义 被引量:3

Tbe clinical significance of the serum CA_(125) level in ovarian cancer
下载PDF
导出
摘要 目的分析卵巢癌手术前后测定血清CA125水平的临床意义.方法采用回顾性分析方法,1994年1月~2000年8月我院收治的137例卵巢癌患者手术前后血清CA125水平结合病理、分期、分化、手术情况\治疗及预后等临床资料进行分析.结果在卵巢癌,术前血清CA125水平与病理类型及分期相关(P=0.006),术后2~4个月血清CA125水平与手术的癌细胞减灭程度相关(P=0.025),术后5~7个月血清CA125水平与是否坚持化疗相关(P=0.014),且为预测复发及生存时间的重要因素.术后血清CA125水平的升高可预测复发,其敏感性为87.5%,且通常较临床证实复发提前,平均为7.2个月.结论卵巢癌患者术前测定血清CA125水平可初步反映病理类型及分期,术后监测血清CA125水平可反映手术的肿瘤减灭程度,及时预测复发,并可判断预后. Objective To evaluate the clinical significance of the serum CA125 level before and after operation of ovarian cancer. Methods 137 patients with ovarian cancer underwent operation in First hospital between January 1994 and August 2000. Correlation analyes among the serum CA125 level and histological type, FTCO stage, cell differentiation, extent of cytoreduc-tion, number of chemotherapy courses, time of recurrence and survival rate were carried out retrospectively. Results The serum CA125 level before operation was related to histological type and FIGO stage (P= 0.006) . The level at 2-4 months after operation was related to the extent of cytoreduction ( P = 0.025) . The level at 5 - 7 months after operation was related to the number of chemotherapy courses and It was also the independent prognostic variable. The increase of the serum CA125 level after operation usually indicated recurrence with asensitivity of 87.5% and the change often occurred 7.2 months (in average) than clinical recurrence. Conclusions The serum CA125 level before operation of ovarian cancer can help to know the histological type and FIGO stage. This marker is useful in the early detection of recurrence. Monitoring it changes after operation can provide the information about the extent of cytoreduction and predict time of recurrence and survival rate.
出处 《中国妇产科临床杂志》 2001年第6期342-344,共3页 Chinese Journal of Clinical Obstetrics and Gynecology
关键词 CA125 卵巢癌 CA_(125) Ovarian neoplasms
  • 相关文献

参考文献11

  • 1[1]Geisler JP, Miller GA, Lee TH, et al. Relationship of preoperative serum CA125 to survival in epithelial ovarian carcinoma. J Reprod Med, 1996, 41: 140- 142 被引量:1
  • 2[2]Jacobs I, Bast RC. The CA125 tumor associated antigen. Review of the literature. Human Reprod, 1989, 4:1 被引量:1
  • 3[3]Markowska J, Wilkoszarska J, Emerich J, et al. Factors influencing period of time between negative second- look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.Eur J Gynaecol Oncol, 2000, 21: 164- 167 被引量:1
  • 4[4]Iwasaka T, Ohkuma Y. Clinical evaluation of specificity ofserum CA125 as a tumor marker of ovarian carcinoma. Nippon Sanka Fujinka Gakkai Zasshi, 1986, 38:917 - 923 被引量:1
  • 5[5]Van der zee AG, Guk JM. The effect of abdominal surgery on the serum concertration of the tumor associated antigen CA125.Br J Obstet Gynecol, 1990, 97:934 被引量:1
  • 6[6]Brun JL, Feyler A, Chene G, et al. Long- term results and prognostic factors in patients with epithelial ovarian cancer. Gynecol Oncol, 2000, 78:21-27 被引量:1
  • 7[7]Molina R, Fileella X. CA125 in biological fluids. Int J Biol Markers, 1998, 13:224-230 被引量:1
  • 8[8]Liu L, Hong W, Hou Y, et al. Evaluation of second- look laparotomy for ovarian cancer: second- look vs. Serum CA125.Chin Med Sci J, 1991, 6:96-99 被引量:1
  • 9[9]Low RN, Saleh F, Song S, et al. Treated ovarian cancer: comparison of MR imaging with serum CA125 level and physical examination- a longitudinal study. Radiology, 1999, 211:519- 528 被引量:1
  • 10[10]Hogdall CK, Hording U, Norgaard- Pedersen B, et al. Serum tetranectin and CA125 used to monitor the course of treatment in ovarian cancer patients. Eur J Obstet Gynecol Reprod Biol,1994, 57: 175- 178 被引量:1

同被引文献37

  • 1连利娟.卵巢肿瘤标志物及其对病情监测的意义[J].实用肿瘤杂志,1993,8(4):195-197. 被引量:9
  • 2[4]Eisenkop S M,Triendman R L,Wang H J.Secondry Cytoreductive surgery for recurrent ovarian cancer[J].Cancer,1995,76:1605-1614. 被引量:1
  • 3[6]Kenemans P,Yedema C A,Bon C G,et al.CA125 in gynerecologic patnologe review[J].Eur J Obstet and Reprod Biol,1993,49:145. 被引量:1
  • 4[7]Robert P W,Mark P C,Fengji X,et al.Combinations of multiple serum markers are superior to indiridual assays for discriminiating malignant from benign pelvicmasses[J].Gynecol Oncol,1995,59:111-116. 被引量:1
  • 5[10]Vander,Zee A G,Guk J M.The effect of abdominal surgery on the serum concertration of the tumor associated antigen CA125[J].Br J Obstet Gynecol,1990,97:934. 被引量:1
  • 6[13]Low R N,Saleh F,Song S,et al.Treated ovarian caner:Comparison of MR image with serum CA125 level and physical examination-a longitudinal study[J].Radiology,1999,211:519-528. 被引量:1
  • 7[17]Vander B M,Lammes F B,Vanputten W L J,et al.The prognostic value of the serum half-time of CA125 during the induction of chemotherapy[J].Gynecol Oncol,1988,39(6):307. 被引量:1
  • 8[18]Hogberg T,Kagedal B.Long-term follow-up of ovarian cancer with monthly determinations of serum CA125[J].Gynecol Oncol,1992,46:191-198. 被引量:1
  • 9[19]Gerado I,Sonia R,Andrea L,et al.Ultrasound,physical examination,and CA125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors[J].Gynecol Oncol,2001,81:63-66. 被引量:1
  • 10李红敏,许青霞,孙萍.血清CA125检测对卵巢癌诊断的意义[J].肿瘤基础与临床,2007,20(5):405-406. 被引量:21

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部